

PROHIBITION OF SALES TO EEA AND UK RETAIL INVESTORS: The Securities are not intended to be offered, sold or otherwise made available to and may not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA") or in the United Kingdom (the "UK"). For these purposes, retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU on Markets in Financial Instruments (as may be amended, varied or replaced from time to time) ("MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97 (the "Insurance Distribution Directive"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in the Prospectus Regulation. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "PRIIPs Regulation") for offering or selling the Securities or otherwise making them available to any retail investors in the EEA or in the UK may be unlawful under the PRIIPs Regulation.

Final Terms dated 1 June 2021

Credit Suisse AG, London Branch

Legal Entity Identifier (LEI): ANGGYXNX0JLX3X63JN86

Trigger Return Equity-linked Securities due June 2024

linked to Sarepta Therapeutics Inc, Neurocrine Biosciences Inc, BioMarin Pharmaceutical Inc and Vertex Pharmaceuticals Inc (the "Securities")

Series SPLB2021-1WSS

ISIN: XS2340991756

issued pursuant to the Trigger Redeemable and Phoenix Securities Base Prospectus

as part of the Structured Products Programme for the issuance of Notes, Certificates and Warrants

PART A - CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such in the General Conditions, the Product Conditions and the applicable Asset Terms (as may be amended and/or supplemented up to, and including, the Issue Date), set forth in the Securities Note dated 10 July 2020, as supplemented on 23 December 2020 and (by a supplement to the Base Prospectus) dated 12 May 2021 and by any further supplements up to, and including, the later of the Issue Date and the date of listing of the Securities (together, the "Securities Note") which, together with the Registration Document dated 7 April 2020, as supplemented on 17 April 2020, 8 May 2020, 5 August 2020, 15 October 2020, 4 November 2020, 7 December 2020, 22 December 2020, 18 January 2021, 26 February 2021, 1 April 2021 and 7 April 2021 and by any further supplements up to, and including, the later of the Issue Date and the date of listing of the Securities (together, the "Registration Document"), constitutes a base prospectus for the purposes of the Prospectus Regulation (the "Base Prospectus"). This document constitutes the Final Terms of the Securities described herein for the purposes of Article 8(4) of the Prospectus Regulation and must be read in conjunction with such Base Prospectus in order to obtain all the relevant information. A summary of the Securities is annexed to these Final Terms. Copies of the documents comprising the Base Prospectus may be obtained from the website of Credit Suisse (https://derivative.credit-suisse.com).

These Final Terms comprise the final terms for the issue and admission to trading on the regulated market of the Luxembourg Stock Exchange of the Securities. The Final Terms will be available on the website of Credit Suisse (https://derivative.credit-suisse.com) and the website of the Luxembourg Stock Exchange (www.bourse.lu).

SPLB2021-1WSS

2 Tranche Number: Not Applicable 3 Applicable General Terms and Conditions: General Note Conditions 4 Type of Security: Trigger Return Securities 5 Settlement Currency: United States Dollar ("USD") 6 Institutional: Not Applicable PROVISIONS RELATING TO NOTES AND CERTIFICATES Applicable Aggregate Nominal Amount: USD 649,000.00 (i) Series:

Series Number:

(ii)

Tranche:

1

8 Issue Price: 100% of the Aggregate Nominal Amount

Not Applicable

9	Specified Den	omination:	USD 1,000.00
10	Minimum Trans	sferable Number of Securities:	Not Applicable
11	Transferable N	lumber of Securities:	Not Applicable
12	Minimum Tradi	ing Lot:	Not Applicable
13	Issue Date:		2 June 2021
14	Maturity Date:		5 Currency Business Days following the Final Fixing Date or, if such date falls on different dates for different Underlying Assets, the latest of such dates to occur (expected to be 4 June 2024)
15	Coupon Basis:		Applicable: Other Coupon Provisions
16	Redemption/F	Payment Basis:	Equity-linked
17	Put/Call Optio	ns:	Not Applicable
PRO	VISIONS RELAT	ING TO WARRANTS	Not Applicable
(Para	graphs 18 to 28	have been intentionally deleted)	
PRO	VISIONS RELAT	ING TO COUPON AMOUNTS	
29	Fixed Rate Pro Certificate Cor	ovisions (General Note Condition 4 or General addition 4):	Not Applicable
30		Provisions (General Note Condition 4 or cate Condition 4):	Not Applicable
31	Premium Provisions (General Note Condition 4 or General Certificate Condition 4):		Not Applicable
32	Other Coupon	Provisions (Product Condition 2):	Applicable
	(i) Coupo	on Payment Event:	Applicable
	(a)	Coupon Amount:	If a Coupon Payment Event has occurred:
			Memory Coupon
			If no Coupon Payment Event has occurred: zero
	(b)	Coupon Payment Event:	On the relevant Coupon Observation Date, the Level (with regard to the Valuation Time) of each Underlying Asset is at or above the Coupon Threshold of such Underlying Asset corresponding to such Coupon Observation Date
	(c)	Coupon Call/Coupon Put:	Not Applicable
	(d)	Memory Coupon:	Applicable
	-	Coupon Rate:	3.5%
	-	t:	In respect of a Coupon Payment Date, the number of Coupon Observation Dates falling in the period commencing on, but excluding, the Issue Date and ending on, and including, such Coupon Payment Date
	(ii) Do	uble No-Touch:	Not Applicable
	(iii) Do	uble No-Touch Accrual:	Not Applicable
	(iv) Double No-Touch Memory:		Not Applicable
	(v) Rai	nge Accrual:	Not Applicable
	(vi) Ste	ep-Up:	Not Applicable
	(vii) Sno	owball:	Not Applicable
	(viii) Ag	gregate Coupon:	Not Applicable
	(ix) Ag	gregate Memory Coupon:	Not Applicable
	(x) Co	upon Cap:	Not Applicable
	(xi) Co	upon Floor:	Not Applicable
	(xii) FX	Adjusted:	Not Applicable

(xiii) Coupon Payment Date(s): In respect of a Coupon Observation Date, 5 Currency Business Days following such Coupon Observation Date (or, if such date falls on different dates for different Underlying Assets, the latest of such dates to occur) (xiv) Coupon Threshold: In respect of a Coupon Observation Date and an Underlying Asset, an amount equal to 70% of the Strike Price of such Underlying Asset (xv) Coupon Threshold (Basket): Not Applicable In respect of an Underlying Asset, each of 25 August 2021, 25 November 2021, 25 (xvi) Coupon Observation Date(s): February 2022, 25 May 2022, 25 August 2022, 25 November 2022, 25 February 2023, 25 May 2023, 25 August 2023, 25 November 2023, 25 February 2024 and (xvii) Coupon Observation Date subject to Valuation Valuation Date adjustment applicable in respect of all Coupon Observation Dates Date adjustment: Coupon Observation Period(s): Not Applicable (xviii) (xix) Coupon Fixing Price: Not Applicable (xx)Coupon Fixing Price Cap: Not Applicable (xxi) Coupon Fixing Price Floor: Not Applicable Coupon Observation Averaging Dates: (xxii) Not Applicable Knock-in Coupon Cut-Off: Not Applicable (xxiii) (xxiv) Lock-in Coupon: Not Applicable PROVISIONS RELATING TO REDEMPTION/SETTLEMENT Redemption Amount or (in the case of Warrants) Settlement Worst of Phoenix Amount (Product Condition 3): (i) Redemption Option Percentage: Applicable: 100 per cent. (ii) Redemption Performance: Not Applicable Redemption Amount Cap/Floor: Applicable (iii) An amount equal to 100 per cent. of the Nominal Amount Redemption Amount Cap 1: Redemption Amount Floor 1: Not Applicable Not Applicable Redemption Amount Cap 2: Redemption Amount Floor 2: Not Applicable Redemption Strike Price: In respect of an Underlying Asset, an amount equal to 60% of the Strike Price of such (iv) Underlying Asset (v) Redemption FX Adjustment: Not Applicable PPT: (vi) Not Applicable (vii) Strike: Not Applicable Nth (for the purposes of determining the Worst (viii) 1st lowest (i.e. the lowest) as specified in Product Condition 1 Performing Underlying Asset): Initial Setting Date: 25 May 2021 Initial Averaging Dates: Not Applicable Final Fixing Date: 25 May 2024 Averaging Dates: Not Applicable Final Price: In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Final Fixing Date Final Price Cap: Not Applicable (i) (ii) Final Price Floor: Not Applicable Strike Price: In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Initial Setting Date (i) Strike Cap: Not Applicable

33

34

35

36

37

38

39

(ii) Strike Floor: Not Applicable 40 Knock-in Provisions: Applicable On the Knock-in Observation Date, the Level (with regard to the Valuation Time) of any (i) Knock-in Event: Underlying Asset is below the Knock-in Barrier of such Underlying Asset (ii) Knock-in Barrier: In respect of the Knock-in Observation Date and an Underlying Asset, an amount equal to 60% of the Strike Price of such Underlying Asset (iii) Knock-in Observation Date(s): 25 May 2024 Knock-in Observation Date subject to Valuation Date Valuation Date adjustment applicable in respect of the Knock-in Observation Date (iv) adjustment: Knock-in Observation Period: Not Applicable (v) Knock-in Fixing Price: (vi) Not Applicable (vii) Redemption Participation: Not Applicable (viii) Not Applicable Floor: Knock-out Event Override Condition: (ix) Not Applicable Knock-out Provisions: 41 Not Applicable 42 Trigger Redemption (Product Condition 3(c)): Applicable (i) Trigger Event: On any Trigger Barrier Observation Date, the Level (with regard to the Valuation Time) of each Underlying Asset is at or above the Trigger Barrier of such Underlying Asset In respect of a Trigger Barrier Observation Date, as specified in the table below in respect (ii) Trigger Barrier Redemption Date(s): of such Trigger Barrier Observation Date In respect of a Trigger Barrier Redemption Date, as specified in the table below in respect Trigger Barrier Redemption Amount: (iii) of such Trigger Barrier Redemption Date (iv) Trigger Barrier: In respect of a Trigger Barrier Observation Date and an Underlying Asset, as specified in the table below in respect of such Trigger Barrier Observation Date Trigger Barrier Observation Date(s): In respect of an Underlying Asset and a Trigger Barrier Redemption Date, as specified (v) in the table below in respect of such Trigger Barrier Redemption Date Trigger Barrier Observation Date subject to Valuation (vi) Valuation Date adjustment applicable in respect of all Trigger Barrier Observation Dates Date adjustment: Trigger Barrier Observation Period(s): (vii) Not Applicable

	Trigger Barrier Observation Date _n	Trigger Barrier _n	Trigger Barrier Redemption Amount _n	Trigger Barrier Redemption Daten
1	25 May 2022	An amount equal to 91% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
2	25 August 2022	An amount equal to 88% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
3	25 November 2022	An amount equal to 85% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
4	25 February 2023	An amount equal to 82% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
5	25 May 2023	An amount equal to 79% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
6	25 August 2023	An amount equal to 76% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
7	25 November 2023	An amount equal to 73% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event

8	25 February 2024	An amount equal to 100 per cent. of the Nominal Amount	5 Currency following the c Trigger Event	Days of a
9	25 May 2024	An amount equal to 100 per cent. of the Nominal Amount	5 Currency following the c Trigger Event	Days of a

	(viii)	Not Applicable		
	(ix) Trigger Barrier Fixing Price:		Not Applicable	
	(x) Trigger Coupon Override Condition:		Not Applicable	
	(xi)	Trigger Knock-out Barrier:	Not Applicable	
	(xii)	Trigger Knock-out Event:	Not Applicable	
	(xiii)	Trigger Knock-out Observation Period Start Date(s):	Not Applicable	
	(xiv)	Trigger Knock-out Observation Period End Date(s):	Not Applicable	
43	Lock-in Redemption: Not Applic			
44	Single Factor Trigger Redeemable (Step-Up) / Single Factor Not Applicable Trigger Redeemable (Star) / Worst of Trigger Redeemable (Step-Up) / Worst of Trigger Redeemable (Star):			
45	Details relating to Instalment Securities: Not Applicable			
46	Physical Settlement Provisions (Product Condition 4): Not Applicable			
47	Put Option: Not Applicable			
48	Call Option: Not Applicable			
49	Unscheduled Termination Amount:			
	(i)	Unscheduled Termination at Par:	Not Applicable	
	(ii)	Minimum Payment Amount:	Not Applicable	
	(iii)	Deduction for Hedge Costs:	Not Applicable	
50	Payment Disruption: Not Applicable			
51	Interest and Currency Rate Additional Disruption Event: Not Applicable			

UNDERLYING ASSET(S)

1

52 List of Underlying Asset(s):

i	Underlying Asset _i	Weight _i	Composite _i
1	The ordinary shares of Sarepta Therapeutics Inc (the "Sarepta Therapeutics Inc Shares")	Not Applicable	Not Applicable
2	The ordinary shares of Neurocrine Biosciences Inc (the "Neurocrine Biosciences Inc Shares")	Not Applicable	Not Applicable
3	The ordinary shares of BioMarin Pharmaceutical Inc (the "BioMarin Pharmaceutical Inc Shares")	Not Applicable	Not Applicable
4	The ordinary shares of Vertex Pharmaceuticals Inc (the "Vertex Pharmaceuticals Inc Shares")	Not Applicable	Not Applicable

Applicable

53 Equity-linked Securities: ApplicableSingle Share, Share Basket or Multi-Asset Basket: Share Basket

(i) Share Issuer: Sarepta Therapeutics Inc

(ii) Share: The Sarepta Therapeutics Inc Shares

 (iii)
 ISIN:
 US8036071004

 (iv)
 Bloomberg Code:
 SRPT UW Equity

(v) Information Source: https://www.nasdag.com NASDAQ Exchange: (vi) Related Exchange: NASDAQ (vii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1 (viii) Adjustment basis for Share Basket and Reference (ix) In respect of the Initial Setting Date, each Coupon Observation Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual Adjustment basis for Share Basket and Averaging Not Applicable (x) Reference Dates: (xi) Trade Date: 25 May 2021 Jurisdictional Event: Not Applicable (xii) (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable (xiv) Share Substitution: Applicable (xv) Additional Disruption Events: Change in Law: Change in Law Option 1 Applicable (a) (b) Foreign Ownership Event: Not Applicable Not Applicable (c) FX Disruption: (d) Insolvency Filing: Applicable (e) Hedging Disruption: Applicable (f) Increased Cost of Hedging: Not Applicable (g) Loss of Stock Borrow: Not Applicable Not Applicable Increased Cost of Stock Borrow: (i) Share Issuer: Neurocrine Biosciences Inc Share: The Neurocrine Biosciences Inc Shares (ii) (iii) ISIN: US64125C1099 NBIX UW Equity (iv) Bloomberg Code: Information Source: https://www.nasdaq.com/ (v) Exchange: NASDAQ (vi) Related Exchange: (vii) All Exchanges (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1 (ix) Adjustment basis for Share Basket and Reference In respect of the Initial Setting Date, each Coupon Observation Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Dates: Share Basket and Reference Dates - Individual / Individual Adjustment basis for Share Basket and Averaging (x) Not Applicable Reference Dates: Trade Date: 25 May 2021 (xi) (xii) Jurisdictional Event: Not Applicable (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable Share Substitution: Applicable (xiv) Additional Disruption Events: (xv) (a) Change in Law: Change in Law Option 1 Applicable (b) Foreign Ownership Event: Not Applicable (c) FX Disruption: Not Applicable (d) Insolvency Filing: Applicable

		(e)	Hedging Disruption:	Applicable
		(f)	Increased Cost of Hedging:	Not Applicable
		(g)	Loss of Stock Borrow:	Not Applicable
		(h)	Increased Cost of Stock Borrow:	Not Applicable
3	(i)	Share	e Issuer:	BioMarin Pharmaceutical Inc
	(ii)	Share	::	The BioMarin Pharmaceutical Inc Shares
	(iii)	ISIN:		US09061G1013
	(iv)	Bloon	nberg Code:	BMRN UW Equity
	(v)	Inforn	nation Source:	http://www.nasdaq.com
	(vi)	Excha	ange:	NASDAQ
	(vii)	Relate	ed Exchange:	All Exchanges
	(viii)	Maxin	num Days of Disruption:	Eight Scheduled Trading Days as specified in Asset Term 1
	(ix)	Adjus Dates	tment basis for Share Basket and Reference ::	In respect of the Initial Setting Date, each Coupon Observation Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual
	(x)		tment basis for Share Basket and Averaging ence Dates:	Not Applicable
	(xi)	Trade	Date:	25 May 2021
	(xii)	Jurisc	lictional Event:	Not Applicable
	(xiii)	Jurisc	lictional Event Jurisdiction(s):	Not Applicable
	(xiv)	Share Substitution:		Applicable
	(xv)	Additi	onal Disruption Events:	
		(a)	Change in Law:	Change in Law Option 1 Applicable
		(b)	Foreign Ownership Event:	Not Applicable
		(c)	FX Disruption:	Not Applicable
		(d)	Insolvency Filing:	Applicable
		(e)	Hedging Disruption:	Applicable
		(f)	Increased Cost of Hedging:	Not Applicable
		(g)	Loss of Stock Borrow:	Not Applicable
		(h)	Increased Cost of Stock Borrow:	Not Applicable
4	(i)	Share	e Issuer:	Vertex Pharmaceuticals Inc
	(ii)	Share	::	The Vertex Pharmaceuticals Inc Shares
	(iii)	ISIN:		US92532F1003
	(iv)	Bloon	nberg Code:	VRTX UW Equity
	(v)	Inforn	nation Source:	http://www.nasdaq.com
	(vi)	Excha	ange:	NASDAQ
	(vii)	Relate	ed Exchange:	All Exchanges
	(viii)	Maxin	num Days of Disruption:	Eight Scheduled Trading Days as specified in Asset Term 1
	(ix)	Adjus Dates	tment basis for Share Basket and Reference ::	In respect of the Initial Setting Date, each Coupon Observation Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual
	(x)		tment basis for Share Basket and Averaging ence Dates:	Not Applicable

25 May 2021

(xi)

Trade Date:

 (xii)
 Jurisdictional Event:
 Not Applicable

 (xiii)
 Jurisdictional Event Jurisdiction(s):
 Not Applicable

 (xiv)
 Share Substitution:
 Applicable

(xv) Additional Disruption Events:

(a) Change in Law: Change in Law Option 1 Applicable

(b) Foreign Ownership Event: Not Applicable (c) FX Disruption: Not Applicable (d) Insolvency Filing: Applicable Hedging Disruption: Applicable (e) (f) Increased Cost of Hedging: Not Applicable Loss of Stock Borrow: (g) Not Applicable

(h) Increased Cost of Stock Borrow: Not Applicable

Index-linked Securities: Not Applicable
 Commodity-linked Securities: Not Applicable
 Commodity Index-linked Securities: Not Applicable

57 ETF-linked Securities: Not Applicable

58 ETC-linked Securities: Not Applicable
 59 FX-linked Securities: Not Applicable

60 FX Index-linked Securities: Not Applicable

Inflation Index-linked Securities: Not Applicable
 Interest Rate Index-linked Securities: Not Applicable

63 Cash Index-linked Securities: Not Applicable
64 Multi-Asset Basket-linked Securities: Not Applicable

65 Valuation Time: As determined in accordance with Equity-linked Securities Asset Term 1

GENERAL PROVISIONS

68

69

66 (i) Form of Securities: Bearer Securities

(ii) Global Security: Applicable
(iii) NGN Form: Not Applicable

(iv) Intended to be held in a manner which would allow Eurosystem eligibility:

No. Whilst the designation is specified as "no" at the date of these Final Terms, should the Eurosystem eligibility criteria be amended in the future such that the Securities are capable of meeting them the Securities may then be deposited with one of the ICSDs as common safekeeper. Note that this does not necessarily mean that the Securities will then be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem at any time during their life. Such recognition will depend upon the European Central Bank being satisfied that Eurosystem eligibility criteria have been met.

(v) The Issuer intends to permit indirect interests in the Securities to be held through CREST Depository Interests to be issued by the CREST Depository: Not Applicable

67 Financial Centre(s): Not Applicable

Business Centre(s): Not Applicable

Application will be made for the Securities to be listed on the Official List of the Luxembourg Stock Exchange and admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from or around the Issue Date provided, however, no assurance can be given that such application for listing and admission to trading will be granted (or, if granted, will be granted by the Issue Date or any specific

date thereafter)

70 Security Codes and Ticker Symbols:

Listing and Admission to Trading:

ISIN: XS2340991756 234099175 Common Code: Swiss Security Number: 59954395 Telekurs Ticker: Not Applicable WKN Number: Not Applicable 71 Clearing and Trading: Clearing System(s) and any relevant identification number(s): Euroclear Bank S.A./N.V. and Clearstream Banking, société anonyme 72 Delivery: Delivery against payment 73 Agents: Calculation Agent: Credit Suisse International One Cabot Square London E14 4QJ United Kingdom Fiscal Agent: The Bank of New York Mellon, acting through its London Branch One Canada Square London E14 5AL United Kingdom The Bank of New York Mellon, acting through its London Branch Paying Agent(s): One Canada Square London E14 5AL United Kingdom Additional Agents: Not Applicable 74 Dealer(s): Credit Suisse International 75 Specified newspaper for the purposes of notices to Not Applicable Securityholders: 76 871(m) Securities: The Issuer has determined that the Securities (without regard to any other transactions) should not be treated as transactions that are subject to U.S. withholding tax under section 871(m) Prohibition of Sales to EEA and UK Retail Investors: 77 Applicable - see the cover page of this Final Terms Applicable - see "Additional U.S. Tax Selling Restrictions" under "UNITED STATES", as Additional U.S. Tax Selling Restrictions: 78 set out in the section headed "Selling Restrictions"

Not Applicable

79

Additional Provisions:

PART B - OTHER INFORMATION

TERMS AND CONDITIONS OF THE OFFER

Not Applicable

INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

So far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the issue, save for any fees payable to the distributor(s).

The Securities will be sold by the Dealer to the distributor(s) at a discount to the Issue Price equivalent of up to 2% of the Specified Denomination per Security. Such discount represents the fee retained by the distributor(s) out of the Issue Price paid by investors. The Issue Price and the terms of the Securities take into account such fee and may be more than the market value of the Securities on the Issue Date.

PERFORMANCE OF SHARE/INDEX/COMMODITY/COMMODITY INDEX/ETF SHARE/ETC/FX RATE/FX INDEX/INFLATION INDEX/INTEREST RATE INDEX/CASH INDEX AND OTHER INFORMATION CONCERNING THE UNDERLYING ASSET(S)

Information on the Underlying Assets, including information about past and future performance as well as volatility, can be found free of charge on the following websites:

(i) Sarepta Therapeutics Inc: https://www.nasdaq.com

(ii) Neurocrine Biosciences Inc: https://www.nasdaq.com/

(iii) BioMarin Pharmaceutical Inc: http://www.nasdaq.com

(iv) Vertex Pharmaceuticals Inc: http://www.nasdaq.com

The information appearing on such websites does not form part of these Final Terms.

The Securities relate to a basket of Underlying Assets. The Securities have a "worst of" feature and therefore no weightings apply.

POST-ISSUANCE INFORMATION

The Issuer will not provide any post-issuance information with respect to the Underlying Assets, unless required to do so by applicable law or regulation.

REASONS FOR THE ISSUE, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

(i) Reasons for the issue: See "Use of Proceeds" section in the Securities Note.

(ii) Estimated net proceeds: USD 649,000.00
(iii) Estimated total expenses: Not Applicable

Signed on behalf of the Issuer:

Julien Bieren Managing Director

Duly authorised

Yogamoorthy Logan Managing Director